English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 toMar 2017. Methodology: A total of 182 consecutive patients with age ≥18 years and positive HCV RNA by polymerasechain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet countof <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes wereexcluded from study. Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients withgenotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients withdual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naive and100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was83.3% (p=0.331) and 88.9% in treatment naive and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia. Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of sideeffects, genotype 3 being the most predominant genotype.

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN